Summary & Overview
HCPCS J0884: Injection, Argatroban 1 mg (ESRD on Dialysis)
HCPCS Level II code J0884 denotes a 1 mg injection of argatroban indicated for patients with end-stage renal disease undergoing dialysis. This code captures administration of a direct thrombin inhibitor used when heparin is contraindicated, and it facilitates accurate reporting and reimbursement for anticoagulant therapy in dialysis settings. Nationally, proper coding of such specialty pharmacologic agents affects dialysis center operations, pharmacy billing workflows, and payer coverage determinations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for argatroban use in dialysis, common billing considerations tied to HCPCS Level II reporting, and what to expect when submitting claims for this agent. The publication summarizes benchmarks where available, highlights relevant policy considerations for national payers, and outlines operational points for dialysis providers and hospital pharmacies handling argatroban dosing and claims.
This content is intended for clinical billing managers, revenue cycle staff, and policy analysts seeking a clear reference on coding and high-level payer coverage landscape for argatroban use in ESRD dialysis patients. Data not available in the input will be noted where applicable in detailed sections.
Billing Code Overview
HCPCS Level II code J0884 represents an injection of argatroban, 1 mg, specified for use in end-stage renal disease (ESRD) patients on dialysis. The service type is pharmacologic anticoagulant administration intended to provide anticoagulation during dialysis procedures for patients with heparin contraindications or heparin-induced thrombocytopenia. The typical site of service is outpatient dialysis units or hospital-based dialysis settings, including in-center hemodialysis environments and hospital dialysis suites.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old with end-stage renal disease on maintenance hemodialysis who requires anticoagulation for dialysis circuit patency due to a history of heparin-induced thrombocytopenia (HIT) or suspected HIT. The patient presents to an outpatient dialysis center or hospital dialysis unit for a scheduled hemodialysis session. The nephrology team or dialysis nurse prepares argatroban as an alternative direct thrombin inhibitor when heparin is contraindicated.
At triage, the patient’s vitals and recent laboratory tests, including activated partial thromboplastin time (aPTT) and platelet count, are reviewed. The provider orders argatroban dosing calculated per institutional protocol for patients with end-stage renal disease on dialysis. The dialysis nurse documents administration of J0884 (argatroban, 1 mg) in the medication administration record, records the lot number and any wastage if partial vial remains, and monitors aPTT and bleeding parameters during and after treatment. The typical site of service is an outpatient dialysis center or inpatient dialysis unit. The service type is medication administration/intravenous anticoagulant for dialysis circuit anticoagulation in patients with ESRD on dialysis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier - standard claim submission |